The announcement additionally noted that throughout 14 months of follow-up, UP421 maintained its pancreatic islet cell ...

In a 14-month follow-up, Sana Biotechnology has found that its investigational allogeneic cell therapy continued to produce insulin in one patient with Type 1 diabetes, with no safety concerns ...

Groundbreaking First-in-Human Study Demonstrates Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without ...

SEATTLE, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (SANA), a company focused on changing the possible for patients through engineered cells, today announced that Cell Stem Cell has ...

(RTTNews) - Sana Biotechnology, Inc. (SANA) announced positive six-month follow-up results Monday from a first-in-human study using UP421—engineered pancreatic islet cells modified with its hypoimmune ...

Shared 12-month clinical results of ongoing UP421 type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted ...

Insulin pumps are the most advanced insulin delivery technology available today for people with type 1 and type 2 diabetes. An insulin pump replaces injections with a syringe or insulin pen, using an ...

REVOLUTIONARY BREAKTHROUGH: Dr. Abhinav Chauhan’s Green Extraction Technology Transforms Black Soldier Fly Waste Into Insulin, Chitosan, Melanin, and other High-Value Pharmaceutical Biomaterials ...

Neuropathy – chronic pain, numbness and tingling in the hands and feet – is a challenging fact of life for many patients with ...

First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results ...